Treatments for fatigue in multiple sclerosis: a rapid and systematic review

Branas P, Jordan R, Fry-Smith A, Burls A, Hyde C

**Record Status**
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

**Citation**

**Authors' objectives**
- To identify current treatments for fatigue in MS and their evidence-base.
- To systematically review the evidence for those treatments that have been investigated in more than one rigorous study, in order to determine their effectiveness and cost-effectiveness.

**Authors' conclusions**
There is insufficient evidence to allow people with MS, clinicians or policy makers to make informed decisions on the appropriate use of the many treatments on offer.

Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term.

**Project page URL**
http://www.hta.ac.uk/1167

**Indexing Status**
Subject indexing assigned by CRD

**MeSH**
Amantadine; Costs and Cost Analysis; Fatigue; Multiple Sclerosis; Pemoline

**Language Published**
English

**Country of organisation**
England

**Address for correspondence**
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

**AccessionNumber**
3200000908

**Date bibliographic record published**
10/11/2000

**Date abstract record published**